KK-LC-1, a biomarker for prognosis of immunotherapy for primary liver cancer.

ABSTRACT:

Purpose

There is mounting evidence that patients with liver cancer can benefit from Immune checkpoint inhibitors. However, due to the high cost and low efficacy, we aimed to explore new biomarkers for predicting the efficacy of immunotherapy.

Methods

Specimens and medical records of liver cancer patients treated at Drum Tower Hospital of Nanjing University were collected, and the expression of Kita-Kyushu lung cancer antigen-1 (KK-LC-1) in tissues as well as the corresponding antibodies in serum were examined to find biomarkers related to the prognosis of immunotherapy and to explore its mechanism in the development of liver cancer.

Results

KK-LC-1 expression was found to be 34.4% in histopathological specimens from 131 patients and was significantly correlated with F

SUBMITTER: Zhu S 

PROVIDER: S-EPMC11229184 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature